Zobrazeno 1 - 10
of 638
pro vyhledávání: ''
Autor:
Jan-Stefan van der Walt, Joji Mori, Takahiro Nakayama, Kenichi Inoue, Yoshinori Ito, George W. Sledge, Yasuo Miyoshi, Tsutomu Kawaguchi, Masato Takahashi, Yoshinori Tanizawa, Masakazu Toi, Antonio Llombart-Cussac, Norikazu Masuda, Hiroji Iwata, Hirofumi Mukai, Sachi Sakaguchi
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-neg
Autor:
Amadou, A., Freisling, H., Jenab, M., Tsilidis, K.K., Trichopoulou, A., Boffetta, P., Van Guelpen, B., Mokoroa, O., Wilsgaard, T., Kee, F., Schöttker, B., Ordóñez-Mena, J.M., Männistö, S., Söderberg, S., Vermeulen, R.C.H., Quirós, J.R., Liao, L.M., Sinha, R., Kuulasmaa, K., Brenner, H., Romieu, I., IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Sub Algemeen Theoretical Physics
Publikováno v:
British Journal of Cancer, 124(11), 1882. Nature Publishing Group
Br J Cancer
Br J Cancer
BACKGROUND: We investigated whether associations between prevalent diabetes and cancer risk are pertinent to older adults and whether associations differ across subgroups of age, body weight status or levels of physical activity. METHODS: We harmonis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f6d0f1003ec6d68dd57d4e02b0c362e
https://ora.ox.ac.uk/objects/uuid:85426259-76ba-4a69-b8d2-4c310484052f
https://ora.ox.ac.uk/objects/uuid:85426259-76ba-4a69-b8d2-4c310484052f
Autor:
Ring, A., Battisti, N.M.L., Reed, M.W.R., Herbert, E., Morgan, J.L., Bradburn, M., Walters, S.J., Collins, K.A., Ward, S.E., Holmes, G.R., Burton, Maria, Lifford, K., Edwards, A., Robinson, T.G., Martin, C., Chater, T., Pemberton, K.J., Brennan, A., Cheung, K.L., Todd, A., Audisio, R.A., Wright, J., Simcock, R., Green, T., Revell, D., Gath, J., Horgan, K., Holcombe, C., Winter, M.C., Naik, J., Parmeshwar, R., Gosney, M.A., Hatton, M.Q., Thompson, A.M., Wyld, L., Collins, K., Ward, S., Holmes, G., Morgan, J., Walters, S., Burton, M., Brain, K., Robinson, T., Pemberton, K., Shrestha, A., Nettleship, A., Richards, P., Harder, H., Audisio, R., Murray, C., Thomson, A.M., Gosney, M., Hatton, M., Armitage, F., Patnick, J., Revill, D., Winter, M.
Publikováno v:
British Journal of Cancer
Background Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is infrequently offered to older individuals. This study determined if there are fit older patients with high-risk disease who may benefit from chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ed056944ecd27827ab3bd963813fe40
http://sro.sussex.ac.uk/id/eprint/101218/1/s41416-021-01388-9.pdf
http://sro.sussex.ac.uk/id/eprint/101218/1/s41416-021-01388-9.pdf
Autor:
Raquel Hernández, Elena Asensio Martínez, Ana Montes, Beatriz Castelo, Jacobo Rogado, Alberto Carmona-Bayonas, V. Pacheco-Barcia, Laura Ciria-Suarez, Mónica Antoñanzas, Caterina Calderon, Francisco Ayala de la Peña, Paula Jiménez-Fonseca, Alejandra Ivars
Publikováno v:
NPJ Breast Cancer
Dipòsit Digital de la UB
Universidad de Barcelona
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Dipòsit Digital de la UB
Universidad de Barcelona
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Quality of life (QoL) is a complex, ordinal endpoint with multiple conditioning factors. A predictive model of QoL after adjuvant chemotherapy can support decision making or the communication of information about the range of treatment options availa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c065ca38eeab048abab9fdbf5f070b1
http://hdl.handle.net/2445/179373
http://hdl.handle.net/2445/179373
Publikováno v:
British Journal of Cancer
Background Some endogenous hormones have been associated with breast cancer risk, but the nature of these relationships is not fully understood. Methods UK Biobank was used. Hormone concentrations were measured in serum collected in 2006–2010, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d482614b3e60f0e3b3fcf0d952cf3d1b
https://ora.ox.ac.uk/objects/uuid:2298adb9-eb05-46ad-ae36-48abd7ac39d1
https://ora.ox.ac.uk/objects/uuid:2298adb9-eb05-46ad-ae36-48abd7ac39d1
Autor:
Miguel Martín, Laia Paré, Barbara Adamo, Roberta Fasani, Blanca Gonzalez-Farre, Benedetta Conte, Giovanna Sabarese, Carlos H. Barrios, Fara Brasó-Maristany, Esther Sanfeliu, Mariavittoria Locci, Giuseppe Perrone, Francesca Zalfa, Esther Barnadas, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, Ana Lluch, Maria Vidal, Joaquín Gavilá, Tomás Pascual, Aleix Prat, Francesco Schettini, Sabino De Placido, Patricia Villagrasa, Vicente Peg, Nuria Chic, Juan Miguel Cejalvo
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Scientia
NPJ Breast Cancer
npj Breast Cancer, Vol 7, Iss 1, Pp 1-13 (2021)
Universidad de Barcelona
Scientia
NPJ Breast Cancer
npj Breast Cancer, Vol 7, Iss 1, Pp 1-13 (2021)
Càncer de mama; Genòmica del càncer; Recerca translacional Cáncer de mama; Genómica del cáncer; Investigación traslacional Breast cancer; Cancer genomics; Translational research Novel antibody-drug conjugates against HER2 are showing high acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c10b99479fa39b069aa421ecf890520
http://hdl.handle.net/2445/175264
http://hdl.handle.net/2445/175264
Autor:
Sylwia Kopijasz, Corran Roberts, Victoria Y Strauss, Shibani Nicum, Andrew R Clamp, Marcia Hall, Richard D. Kennedy, Ana Montes, Charlie Gourley, Jacinta Abraham, Michael R.L. Stratford, Susana Banerjee, Lisa K. Folkes
Publikováno v:
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4, https://doi.org/10.1038/s41416-019-0674-4
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
BackgroundTumour cells with BRCA1/2 gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. 6-mercaptopurine (6MP) was found to selectively kill BRCA-defective cells in a xenograft model as eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2b494bdec4a88dbce8776a6e9b65b9c
https://doi.org/10.1038/s41416-019-0674-4
https://doi.org/10.1038/s41416-019-0674-4
Publikováno v:
British Journal of Cancer
Background Previous studies suggest a protective role of physical activity in breast cancer risk, largely based on self-reported activity. We aimed to clarify this association by examining breast cancer risk in relation to self-reported physical acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a722803fcba970203601d360bcec4002
https://ora.ox.ac.uk/objects/uuid:1e16a41e-f248-4e0f-8e5c-c35bdc9bd92c
https://ora.ox.ac.uk/objects/uuid:1e16a41e-f248-4e0f-8e5c-c35bdc9bd92c
Autor:
Miguel Gil-Gil, José A. García-Sáenz, E Dalmau Portulas, Elena García-Martínez, Nuria Ribelles, A. Santaballa Bertran, E. Martínez de Dueñas, I Alvarez-Lopez, Susana Bezares
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Clinical & Translational Oncology
Universidad de Barcelona
Clinical & Translational Oncology
PurposeHormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b63a263cb82f360402dddafab187eefb
http://hdl.handle.net/2445/174389
http://hdl.handle.net/2445/174389
Autor:
Masako Sato, Hidetoshi Kawaguchi, Satoshi Morita, Makiko Mizutani, Yoshie Hasegawa, Ken-ichi Watanabe, Yasuaki Sagara, Fumikata Hara, Takashi Morimoto, Takahiro Nakayama, Norikazu Masuda, Mitsuya Itoh, Shoichiro Ohtani, Nobuki Matsunami, Kenji Higaki, Masato Takahashi, Tetsuhiro Yoshinami
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This study aimed to investigate whether schedule modification is safe and effective in patients intolerant to the standard eribulin dose and schedule. Methods Patients with metastatic breast cancer (MBC) treated with both anthracycline and